Inmunoterapia "STAb" para el tratamiento de neoplasias hematológicas
- RAMÍREZ FERNÁNDEZ, ÁNGEL
- Belén Blanco Durango Zuzendaria
- Luis Álvarez Vallina Zuzendaria
Defentsa unibertsitatea: Universidad Complutense de Madrid
Fecha de defensa: 2022(e)ko uztaila-(a)k 06
- José Ramón Regueiro González-Barros Presidentea
- Joaquín Martínez López Idazkaria
- Silvia Martin-Lluesma Kidea
- Natalia Gómez Lozano Kidea
- Francisco Martín Molina Kidea
Mota: Tesia
Laburpena
Cancer immunotherapy has progressed significantly with the emergence of potentially curative strategies for B-cell acute lymphoblastic leukemia (B-ALL). The most effective approaches are based on the use of anti-CD19 x anti-CD3 bispecific antibodies,and adoptive cell therapies with engineered T lymphocytes expressing a chimeric antigen receptor (CAR) that recognizes the CD19 molecule (CAR-T19). The administration of CAR-T19 cells and the systemic infusion of anti-CD19 x anti-CD3 bispecific T cell engagers (BiTEs) have demonstrated a remarkable response rate in patients with refractory or relapsed B-ALL (R/R B-ALL). However, despite the excellent results reported, 30-60% of treated patients relapse or progress within one year of treatment. In our laboratory, we have developed the immunotherapy STAb (Secretion of T cell redirecting bispecific Antibodies)-T, which consists of the modification of T cells to secrete T cell engagers (TCEs)...